MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Apyx Medical Corporation Net Income 2011-2026 | APYX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Apyx Medical Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.7 M | -23.2 M | -15.2 M | -11.9 M | -19.7 M | 64 M | -5.06 M | -3.95 M | -5.37 M | -17.3 M | -4.34 M | 617 K | 109 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 64 M | -23.2 M | -4.61 M |
Quarterly Net Income Apyx Medical Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.98 M | -3.78 M | -4.15 M | - | -4.7 M | -6.56 M | -7.58 M | - | -4.63 M | -994 K | -3.48 M | - | -5.76 M | -5.43 M | -5.94 M | - | -4.22 M | -4.05 M | -4.9 M | - | -3.73 M | -4.69 M | -1.95 M | - | -4.37 M | -4.34 M | -5.61 M | -3.33 M | 68.5 M | -2.94 M | -935 K | -2.97 M | -1.24 M | -1.31 M | -1.68 M | -523 K | -965 K | -519 K | -1.94 M | -1.41 M | -1.59 M | -1.5 M | -876 K | -5.45 M | -2.98 M | 29 K | -9.81 M | -5.12 M | -4.34 M | -4.34 M | -4.34 M | 285 K | 617 K | 617 K | 617 K | -875 K | 109 K | 109 K | 109 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 68.5 M | -9.81 M | -1.56 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M |  USA |
 |
Cognyte Software Ltd.
CGNT
|
-12.1 M | $ 7.25 | -8.17 % | $ 521 M |  Israel |
 |
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | USA |
 |
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | USA |
 |
Acutus Medical
AFIB
|
-81.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | USA |
 |
Aziyo Biologics
AZYO
|
-37.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Alphatec Holdings
ATEC
|
-162 M | $ 13.48 | -4.13 % | $ 1.93 B | USA |
 |
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | USA |
 |
EDAP TMS S.A.
EDAP
|
-19 M | $ 4.08 | 0.37 % | $ 152 M |  France |
 |
Bio-Rad Laboratories
BIO
|
-716 M | $ 299.07 | -2.23 % | $ 8.44 B | USA |
 |
Bruker Corporation
BRKR
|
113 M | $ 41.06 | -3.54 % | $ 6.12 K | USA |
 |
BioSig Technologies
BSGM
|
-10.3 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
1.85 B | $ 78.26 | 3.65 % | $ 115 B | USA |
 |
Abbott Laboratories
ABT
|
13.4 B | $ 109.11 | 0.84 % | $ 190 B | USA |
 |
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | USA |
 |
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | USA |
 |
ClearPoint Neuro
CLPT
|
-18.9 M | $ 12.43 | -6.61 % | $ 336 M | USA |
 |
CONMED Corporation
CNMD
|
132 M | $ 40.63 | 1.75 % | $ 1.25 B | USA |
 |
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | USA |
 |
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | USA |
 |
Cutera
CUTR
|
-57.2 M | - | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M |  Canada |
 |
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | USA |
 |
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
7.54 M | $ 28.95 | -0.96 % | $ 245 M | USA |
 |
InMode Ltd.
INMD
|
181 M | $ 14.77 | -1.66 % | $ 1.17 B | Israel |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Second Sight Medical Products
EYES
|
-23.5 M | - | -0.97 % | $ 54.4 M | USA |
 |
Profound Medical Corp.
PROF
|
-30.7 M | $ 6.35 | -6.89 % | $ 180 M | Canada |
 |
Align Technology
ALGN
|
421 M | $ 176.77 | 9.59 % | $ 13.2 B | USA |
 |
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | USA |
 |
FONAR Corporation
FONR
|
12.4 M | $ 18.54 | 0.11 % | $ 122 M | USA |
 |
Globus Medical
GMED
|
103 M | $ 87.55 | 0.56 % | $ 11.9 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
-6.94 M | $ 10.94 | -1.26 % | $ 842 M | USA |
 |
Establishment Labs Holdings
ESTA
|
-84.6 M | $ 66.7 | -3.52 % | $ 1.88 B |  Costa-rica |
 |
IRIDEX Corporation
IRIX
|
-9.57 M | $ 1.45 | 0.69 % | $ 23.4 M | USA |
 |
IRadimed Corporation
IRMD
|
19.2 M | $ 94.23 | 0.4 % | $ 1.19 B | USA |
 |
Integer Holdings Corporation
ITGR
|
120 M | $ 85.94 | 0.49 % | $ 2.89 B | USA |
 |
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-20.7 M | $ 0.67 | 0.3 % | $ 36.5 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-37.8 M | $ 16.64 | -1.54 % | $ 384 M | USA |